继续或继续使用恩替卡韦治疗的乙型肝炎E抗原阴性非肝硬化

StephenW

J Infect Dis. 2019 Jan 17. doi: 10.1093/infdis/jiy697. [Epub ahead of print]
The Incidence of Hepatitis B Surface Antigen Loss Between Hepatitis B E Antigen-Negative Noncirrhotic Patients Who Discontinued or Continued Entecavir Therapy.
Chen CH1, Hung CH1, Wang JH1, Lu SN1, Lai HC2, Hu TH1, Lin CH2, Peng CY2,3.
Author information

1
    Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine.
2
    Division of Hepatogastroenterology, Department of Internal Medicine.
3
    School of Medicine, China Medical University, Taichung, Taiwan.

Abstract
Background:

We compared rates of hepatitis B surface antigen (HBsAg) loss and hepatocellular carcinoma (HCC) development in hepatitis B e antigen (HBeAg)-negative patients without cirrhosis who continued or discontinued entecavir.
Methods:

Patients who discontinued entecavir treatment for at least 12 months (discontinued group; n = 234) and patients who continued entecavir treatment for at least 4 years (continued group; n = 226) were recruited.
Results:

In the discontinued group, the 5-year cumulative incidences of virological relapse (VR), clinical relapse (CR), and HBsAg loss were 71.9%, 58.9%, and 13%, respectively. Patients with sustained response, VR but no CR, and CR without retreatment were 49-, 13-, and 18-fold more likely to develop HBsAg loss than those with retreatment. Patients who discontinued entecavir therapy had a higher rate of HBsAg loss than those who continued entecavir therapy, in all and 360 propensity score (PS)-matched patients. Cox regression analysis revealed that the discontinued group was an independent predictor for HBsAg loss. There was no significant difference in HCC development between the 2 groups in all and PS-matched patients.
Conclusions:

HBeAg-negative patients without cirrhosis who discontinued entecavir treatment exhibited a higher HBsAg loss rate without an increased risk of HCC compared to those who continued entecavir treatment.

PMID:
    30689910
DOI:
    10.1093/infdis/jiy697

StephenW

J Infect Dis。 2019年1月17日doi：10.1093 / infdis / jiy697。 [印刷前的电子版]
继续或继续使用恩替卡韦治疗的乙型肝炎E抗原阴性非肝硬化患者乙型肝炎表面抗原丢失的发生率。
Chen CH1，Hung CH1，Wang JH1，Lu SN1，Lai HC2，Hu TH1，Lin CH2，Peng CY2,3。
作者信息

1
    高雄长庚纪念医院和长庚大学医学院内科，肝内科，肝内科。
2
    内科，肝脏胃肠病学科。
3
    中国医科大学医学院，台湾台中。

抽象
背景：

我们比较了继续或停用恩替卡韦的乙型肝炎e抗原（HBeAg）阴性无肝硬化患者的乙型肝炎表面抗原（HBsAg）丢失和肝细胞癌（HCC）发生率。
方法：

招募停用恩替卡韦治疗至少12个月（停药组; n = 234）和继续接受恩替卡韦治疗至少4年（继续组; n = 226）的患者。
结果：

在已停产的组中，病毒学复发（VR），临床复发（CR）和HBsAg损失的5年累积发生率分别为71.9％，58.9％和13％。具有持续反应，VR但没有CR和没有再治疗的CR的患者发生HBsAg丢失的可能性比再治疗患者高49,13和18倍。在所有和360倾向评分（PS）匹配的患者中，停用恩替卡韦治疗的患者的HBsAg消失率高于继续接受恩替卡韦治疗的患者。 Cox回归分析显示，停用组是HBsAg丢失的独立预测因子。在所有和PS匹配的患者中，两组之间的HCC发展没有显着差异。
结论：

与继续接受恩替卡韦治疗的患者相比，停用恩替卡韦治疗的无肝硬化的HBeAg阴性患者表现出较高的HBsAg丢失率而没有增加的HCC风险。

结论：
    30689910
DOI：
    10.1093 / infdis / jiy697